Effective and well tolerated: where do these drugs fit now?
Mené sur 1 401 patients atteints d'un cancer de la prostate non métastatique résistant à la castration, cet essai de phase III évalue, du point de vue de la survie sans métastases, de la progression de la douleur et de la qualité de vie, l'intérêt de l'enzalutamide (durées médianes de suivi : 18,5 mois et 15,1 mois)
In The Lancet Oncology, Bertrand Tombal and colleagues describe the health-related quality of life (HRQOL) reported by participants in the PROSPER study, the main endpoints of which were published by Hussain and colleagues in 2018. The trial identified a significant improvement in metastasis-free survival for men with non-metastatic, but castrate-resistant, prostate cancer who received enzalutamide in addition to standard androgen deprivation therapy, compared with those who received placebo. However, particularly for interventions designed to improve survival rather than achieve cure, there is a major trade-off that patients have to consider. What is the balance between improved survival versus extra toxicity or loss of HRQOL that the additional therapy can cause?
The Lancet Oncology , commentaire, 2018